Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prime Therapeutics and EMD Serono Ink Value-Based Agreement on MAVENCLAD\u00ae (Cladribine) Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prime Therapeutics and Takeda Agree to Outcomes-Based Arrangement for Hemophilia A Treatment ADVATE\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Prime Therapeutics

    Menu

    Prime Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Prime Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Prime Therapeutics and Takeda Agree to Outcomes-Based Arrangement for Hemophilia A Treatment ADVATE®

              Details:

              ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A. The arrangement between Prime and Takeda provides an opportunity to assess clinical outcomes and cost implications with an existing treatment for hemophilia A.

              Lead Product(s): Antihemophilic factor recombinant

              Therapeutic Area: Genetic Disease Product Name: ADVATE

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Takeda Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Prime Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Prime Therapeutics and EMD Serono Ink Value-Based Agreement on MAVENCLAD® (Cladribine) Tablets

              Details:

              The arrangement aims to provide financial compensation for Blue Plans that is dependent on the rate at which their members discontinue the two-year treatment with MAVENCLAD or switch to a different MS therapy at any point over the typical course of treatment.

              Lead Product(s): Cladribine

              Therapeutic Area: Neurology Product Name: Mavenclad

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: EMD Serono

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY